About pulmo biotech inc. - PLSE
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.
PLSE At a Glance
Pulse Biosciences, Inc.
601 Brickell Key Drive
Miami, Florida 33131
| Phone | 1-510-906-4600 | Revenue | 0.00 | |
| Industry | Medical Specialties | Net Income | -53,585,000.00 | |
| Sector | Health Technology | Employees | 75 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
PLSE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 9.993 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -17.065 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.01 |
PLSE Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -714,466.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PLSE Liquidity
| Current Ratio | 11.88 |
| Quick Ratio | 11.88 |
| Cash Ratio | 11.739 |
PLSE Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -54.999 |
| Return on Equity | -67.309 |
| Return on Total Capital | -43.298 |
| Return on Invested Capital | -61.292 |
PLSE Capital Structure
| Total Debt to Total Equity | 7.747 |
| Total Debt to Total Capital | 7.19 |
| Total Debt to Total Assets | 6.638 |
| Long-Term Debt to Equity | 6.567 |
| Long-Term Debt to Total Capital | 6.095 |